Serum complement levels were assayed in 26 patients with disseminated cancer, who received immunotherapy with infusion of C. parvum. Complement activation, indicated by the consumption of C3 or C4 or both, was found in 46°' of the
patients.
Serum samples showed direct correlation between decreased C3 and conversion of C3 proactivator, whereas such conversion did not occur when C4 alone was decreased. It is concluded that the bypass (properdin) pathway was activated in patients in whom C3 consumption was detected, while the classical (Cl) pathway was activated in the patients with C4 consumption unaccompanied by C3 decrease. Direct correlation was observed between delayed cutaneous hypersensitivity reactions to recall antigens and the incidence of C. parvum-associated complement activation.
CLINICAL interest in the immunotherapeutic potential of the anaerobic bacterial species Corynebacterium parvum (C. parvrum) was stimulated by the demonstration in animal models that C. parvum augments resistance to infections (Adlam, Broughton and Scott, 1972; Halpern et al., 1973) and protects against graft-versus-host disease (Howard et al., 1967) . Administration of C. parv,um may prevent tumour engraftment (WA'oodruff and Boak, 1966) , prolong survival (Halpern et al., 1966) , or induce long-lasting regression of established tumours (Likhite and Halpern, 1974) in animals.
The recent demonstration in mice of regression of Lewis lung carcinoma metastases following parenteral administration of C. parvrum (Milas et al., 1974) , has prompted clinical trials of immunotherapy with C. parrurn in metastatic human cancer (Band et al., 1975; Reed et al., 1975) .
Infusion of C. parrrun into the circulation might be expected to activate the C3 bypass (properdin) pathway (Gotze and Muller-Eberhard, 1971 ) by virtue of bacterial-wall polysaccharide and lipopolysaccharide constituents (Gewurtz, Shin and Morgenhagen, 1968) .
Since naturally occurring antibodies to C. parvum may circulate in cancer patients (James et al., 1975) , i.v. C. parvrum may result in the immediate formation of antigen-antibody complexes capable of activating the Cl (classical) pathway (Ruddy, Gigli and Austen, 1972) . Additionally, following repeated antigenic stimulation by i.v. C, parvum, specific antibody production may result in immune complex-induced activation of C1.
Recently, it has been demonstrated that complement components are activated when C. parrum is added to guineapig or human serum in vitro .
The present study was designed to determine if complement activation occurs in vivo in cancer patients receiving immunotherapy with C. parvum.
MATERIALS AND METHODS
Twenty-six patients with disseminated cancer who had been selected for a Phase I trial of i.v. C. parvum immunotherapy were evaluated for C. parvum-associated complement activation.
Clinical and histological diagnoses were: melanoma (16 patients), acute leukaemia (3), colon carcinoma (3), lung carcinoma (2), lymphoma (1), and carcinoid (1).
Patients received killed, endotoxin-free (Limulus test negative) C. parvum suspensions (Burroughs Wellcome Research, Triangle Park, North Carolina) during intervals between courses of chemotherapy.
Each immunotherapy treatment consisted of a single i.v. C. parvum dose. Individual doses of C. parvum, ranging from 1 to 10 mg/M2, were infused over 1-h periods. The same C. parvum dosage was maintained throughout the treatment course for each patient.
In order to evaluate serum complement changes, each patient was followed at sequential C. parvum treatments, and served as his own control. For complement component determination, venous blood samples were obtained before, and 2 h after, the completion of each C. parvum infusion. Serum was separated within 30 min and stored at -70°C.
Serum levels of C4 and C3 were determined by haemolytic assays, as previously described (Vroon, Schultz and Zarco, 1970; Moake and Schultz, 1975) . Cellular intermediates (EACI, EAC1-4) and complement components (C2, C5-9) were obtained from Cordis Laboratories, Miami, Florida. Individual and pooled normal serum samples were always included as controls. The titre of the control samples ranged as follows: C3 (mean : s.d.) 26,100 ± 21,500; C4, 92,400 ± 43,600, CH50 u/ml. Complement activation was considered to have occurred if there was at least a four-fold decrease in serum titres of C4 or C3 (or both), as compared to pre-C. parvum levels. If a four-fold (2 tubes dilution difference) or greater decrease in haemolytic titre was observed during the time interval between the completion of one C. parvum infusion and the subsequent infusion, complement activation was considered to have occurred in the absence of evidence for intervening infection (Fearon et al. 1975 ). This late activation was considered to be "delayed ". Complement activation detected within 2 h following C. parvurn infusion was defined as " immediate ".
Conversion of the C3-proactivator (C3PA) to its activated form (C3A) was determined by immunoelectrophoresis as previously described (Wands et al., 1975) . Fresh normal human serum (NHS) and zymozan-activated NHS served respectively as negative and positive controls. Appearance in tested serum of C3A with gamma mobility, similar to that seen in zymozan-activated NHS, indicated activation of C3 proactivator. Anti-C3 activator was obtained from Behringwerke AG., Marburg-Lahn, West Germany.
While on C. parvurm immunotherapy the patients' cell-mediated immunocompetence was evaluated by skin testing with recall antigens (Dermatophytin, Dermatophytin-0, Varidase, Candida, Mumps and PPD), and by primary sensitization to Keyhole Limpet Haemocyanin (KLH) and to dinitro-chlorobenzene (DNCB) (Gutterman et al., 1973) .
Positive reaction to at least 2 recall antigens of 5-mm induration was required for a patient to be classified as " recall antigen positive ".
Statistical analysis of the correlation between complement activation and delayed hypersensitivity skin reactions was performed by the x2 test.
RESULTS
The incidence ofimmediate and delayed complement consumption relative to the number of patients and to the total number of C. parvum infusions is shown in Table I . Complement component consumption was detected in 12 (46%) of 26 patients. In 11 of these 12 patients, consumption was of the immediate type. Of 60 total C. parvum infusions, 16 (26.6%) were followed by complement consumption of either the immediate (12) or delayed (4) type. C4 or C3 components were consumed following 14 of 60 C. parvum infusions (Table II) . Both C4 and C3 were simultaneously consumed after 2 infusions. Immediate and de- layed consumption was almost equal for C4, whereas C3 consumption was predominantly of the immediate type. The 4 instances of delayed consumption occurred 1-13 days (median = 7 days) after C. parvum administration. C4 consumption following the first treatment of C. parvum was observed in 3 patients, whereas consumption of C3 was only observed subsequent to the second C. parvum treatment and thereafter (Table III) .
Complement consumption was repeatedly demonstrated in 4 patients. In all of these, C4 consumption preceded that of C3. Concomitant consumption of C4 and C3 was detected in only 2 instances and did not occur before the fifth C. parvum infusion. No correlation could be demonstrated between the dose of C. parvutm infused and the incidence or degree of complement consumption (Table IV) .
Also, no dose-related differences were observed between C4 vs. C3 consumption. Following consumption, complement component levels were subsequently restored to normal levels within 7 to 36 days (median 20 days).
Nine serum samples of patients in whom complement consumption had occurred were assayed for the presence of C3PA and its activated form, C3A. As shown in Table V , conversion to the activated form occurred when C3 was consumed. In contrast, consumption of C4, unaccompanied by that of C3, was not associated with conversion of the proactivator. In the category of concomitant Both complement activation and delayed hypersensitivity skin reaction were studied in 15 patients. In these 15, complement activation was detected in 8. All 8 reacted positively to at least 2 recall antigens (Table VI ).
In 7 patients with no demonstrable C. parvum-associated complement activation only 2 had positive reactivity to recall antigens (P < 0.05). No apparent relationship was observed between reactivity to PPD, KLH or DNCB and complement activation. The survival, from initiation of C. parvum therapy, of patients whose serum complement was activated, was slightly, but not significantly, longer than that of patients in whom complement activation was not detected (median survival: 6 months for the former, 5 months for the latter group; P > 0 05, by the general Wilcoxon test).
DISCUSSION
The results of this study indicate that i.v. administration of C. parvum induces consumption of complement components in a substantial proportion of patients with disseminated cancer. In the majority of cases, complement component consumption consistently showed a close time relationship to C. parvum administration, and there was no evidence for induction of complement activation by factors other than C. parvrum. In the few cases where activation was delayed 1-13 days (median 7 days) we cannot exclude the theoretical possibility that the phenomenon was not C. parvum-related. Either the " classical " (CI, 2, 4) or the C3 bypass (properdin) pathway may be activated. The association between C3 consumption and the conversion of C3PA to its activated form, as opposed to lack of such conversion when only C4 was consumed in the sampled sera, supports the contention that isolated C4 consumption reflects classical pathway activation (Cooper, 1973) , whereas C3 consumption indicates activation of the bypass pathway following C. parvrum infusion. Complement activation through the classical pathway is usually induced by C1 attachment to IgM, IgG1, IgG2 or IgG3, after the formation of antigen-antibody complexes (Ruddy et al., 1972) . Such complex formation may follow i.v. administration of C. parvum, since naturally occurring antibodies to C. parvum have been demonstrated in humans (James et al., 1975) as well as in mice Woodruff, McBride and Dunbar, 1974) . Furthermore, anti-C. parrum antibody responses have been described in cancer patients treated with parenteral C. parvumr. The immunoglobulin responses were primarily of IgG type and consisted mainly of the JgG2 and IgG1 sub-classes (James et al., 1975) . Consequently, single or repeated C. parvum infusion may result in circulating antigenantibody complexes and activation of the classical complement pathway through C11. Consumption of C4 immediately following the first C. parvum treatment, observed in some of our patients, is consistent with the presence of pre-existing circulating antibodies to C. parvrum and activation of complement through the classical pathway. The occurrence of classical pathway activation only in a portion of the studied patient population could be explained by possible variation in the level of circulating anti-C. parvum antibodies in this population. This factor, combined with the variation in C. parrum dose administered, would result in variable antigen: antibody ratio and consequently, different conditions for formation of circulating immune complexes in different individuals. In other patients, properdin pathway activation, detected after C. parvam infusion may have been induced by C. parvuni cell-wall polysaccharide (Dawes, Tuach and McBride, 1974). V'arious bacterial and fungal polysaccharides and lipopolysaccharides have been shown to activate the properdin pathway ((ewurtz et al., 1968; Gotze and Muller-Eberhard, 1971 ). This direct effect may be inversely related to the capacity of the reticulo-endothelial system (RES) to remove C. parrum organisms from the circulation (Fearon et al., 1975) . Variable RES capacity to clear particulate matter, which can be either enhanced by stimulants such as C. parrum (Halpern et al., 1973) or blocked by excessive load of repeatedly infused stimulant or other phagocytosed material, could account for the incidence of bypass (properdin) activation, as observed in this studv. Since circulating antigen-antibody complexes may also be removed by the RES, the observed incidence of Cl pathway activation could have been affected by this factor as well. Recently, a decrease in serum C3 level after completion of i.v. C. parvrum therapy in patients with disseminated cancer has been reported (Israel et al., 1975) .
C. parvrum treatment, delayed hypersensitivity and complement activation, may all be linked to macrophage activation. There is a growing body of evidence suggesting that C. parvrum activates macrophages, and these are currently believed to mediate some of its antitumour effects (Ghaffar, Cullen and Woodruff, 1975; Olivotto and Bomford, 1974; Wolmark and Fisher, 1974) . Second, macrophage infiltration is a major component of delayed hypersensitivity skin reactions (Dannenberg, 1975) . Third, macrophages may also interact with complement by virtue of their complement receptors (Rowlands and Daniele, 1975) . It has been suggested that C3 decrease observed in cancer patients after repeated C. parvrum infusions may be due to increased consumption byactivated macrophages (Israel et al., 1975) . Such a mechanism could operate in those of our patients whose complement components consumption was delayed, but it is unlikely to account for C4 or C3 consumption when it occurred immediately following C. parvum infusion. Of particular interest is the evidence, reported very recently, that activated complement components (e.g. C3b) can induce lysosomal enzyme release from macrophages in vitro (Schorlemmer, Davies and Allison, 1976) . If this is true in vivo it could help elucidate the mechanism by which macrophages are activated by C. parrum.
In addition to macrophages, bonemarrow-derived lymphocytes may also be involved in the complex of cellular and humoral immunological reactions triggered by C. parvrum since they are also activated by this immunotherapeutic agent (Howard, Scott and Christie, 1973) . Some bone-marrow-derived lymphocytes carry complement receptors (Jaffe et al., 1974) and may, upon interaction with complement, liberate certain lymphokines (Wahl, Iverson and Oppenheim, 1974) . The latter, prepared in vitro and injected into tumour nodules, have been recently shown to augment delayed hypersensitivity and induce tumour regression (Klein, et al., 1975) .
Survival analysis comparing C. parvumtreated patients according to whether serum complement was activated or not, showed only slight advantage associated with complement activation, with no statistical significance. However, only patients with advanced metastatic disease were included in this Phase I study, and therefore projection cannot be made from this study on the possible effect of C. parvum-associated complement activation on survival of patients with less advanced cancer.
Complement has recently been shown to form complexes with antibodies on the surface of human cancer cells in vivo (Irie, Irie and Morton, 1975) . Also, it is noteworthy that some polysaccharides with anti-tumour activity have been reported to activate complement in vitro (Okuda et al., 1972) . Furthermore, quantitative correlation has been demonstrated between C3-activating capacity in vitro and the protection conferred in vivo by the same polysaccharides against tumour transplantation (Nishioka, 1975) . It is conceivable that under different circumstances (i.e., less advanced disease) C. parvum-associated complement activation may play an important role in the host defence against the tumour. 
